Authors

• Andrew N. Priest (ORCID: https://orcid.org/0000-0002-9771-4290)
• João Duarte (ORCID: https://orcid.org/0000-0002-6116-942X)
• Sarah J. Welsh (ORCID: https://orcid.org/0000-0001-5690-2677)
• Iosif Mendichovszky (ORCID: https://orcid.org/0000-0002-3777-2827)
• Mary A. McLean (ORCID: https://orcid.org/0000-0002-3752-0179)
• Anne Y. Warren (ORCID: https://orcid.org/0000-0002-1170-7867)
• Ines Horvat‐Menih (ORCID: https://orcid.org/0000-0002-1373-6944)
• Ferdia A. Gallagher (ORCID: https://orcid.org/0000-0003-4784-5230)
• Alixander S. Khan (ORCID: https://orcid.org/0000-0002-9048-9553)
• James O. Jones (ORCID: https://orcid.org/0000-0002-2194-4903)
• Marta Wylot
• M. Locke (ORCID: https://orcid.org/0000-0003-3481-2691)
• Joshua Kaggie (ORCID: https://orcid.org/0000-0001-6706-3442)
• Andrew B. Gill (ORCID: https://orcid.org/0000-0002-9287-9563)
• Grant Duncan Stewart (ORCID: https://orcid.org/0000-0003-3188-9140)
• Thomas J. Mitchell (ORCID: https://orcid.org/0000-0003-0761-9503)
• Maria Jesus Zamora Morales
• Hao Li (ORCID: https://orcid.org/0000-0002-7712-0890)
• James N. Armitage

Institutions

• University of Cambridge (GB)
• Cambridge University Hospitals NHS Foundation Trust (GB)
• Shanghai Center for Brain Science and Brain-Inspired Technology (CN)

Publication Details

Journal

BMJ Open

Published

2024-10-01

DOI

https://doi.org/10.1136/bmjopen-2024-083980

Citations

4

Primary Topic

Renal cell carcinoma treatment

Type

article

Field-Weighted Citation Impact

1.68

Funders

• Pfizer
• AstraZeneca
• GlaxoSmithKline
• Intuitive Surgical
• Cancer Research UK
• National Institute for Health and Care Research
• EUSA Pharma